0.00

100.00% -3.65

After Hours: 3.66 3.66 +

Revance Therapeutics Inc (RVNC)

Overview News Price History Option Chain Financials Why RVNC Down? Discussions Forecast

Revance Therapeutics Inc stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month. Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Previous Close:

$3.65

Open:

24h Volume:

Relative Volume:

0.00

Market Cap:

$381.02M

Revenue:

$234.04M

Net Income/Loss:

$-323.92M

P/E Ratio:

0.00

EPS:

-3.8

Net Cash Flow:

$-223.46M

1W Performance:

-100.00%

1M Performance:

-100.00%

6M Performance:

-100.00%

1Y Performance:

-100.00%

1-Day Range:

$0.00

1-Week Range:

$0.00

$3.66

52-Week Range:

$0.00

$7.56

Revance Therapeutics Inc Stock (RVNC) Company Profile

Name

Revance Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (678)

Phone

(615) 724-7755

Address

1222 DEMONBREUN STREET, NASHVILLE, CA

Employee

597

Twitter

@revance

Next Earnings Date

2024-11-04

Latest SEC Filings

RVNC's Discussions on Twitter

Compare RVNC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RVNC Revance Therapeutics Inc	0.00	381.02M	234.04M	-323.92M	-223.46M	-3.80
VRTX Vertex Pharmaceuticals Inc	455.22	117.23B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	665.46	72.75B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	636.02	38.65B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	268.99	34.69B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	114.50	27.45B	3.30B	-501.07M	1.03B	-2.1146

Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-29-24	Downgrade	Mizuho	Buy → Neutral
Jan-09-24	Downgrade	Goldman	Buy → Neutral
Aug-16-23	Upgrade	Exane BNP Paribas	Underperform → Neutral
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight
Sep-22-22	Initiated	Goldman	Buy
Oct-25-21	Downgrade	Wells Fargo	Overweight → Equal Weight
Oct-15-20	Reiterated	Needham	Buy
Aug-11-20	Resumed	Mizuho	Buy
Mar-23-20	Downgrade	Goldman	Buy → Neutral
Dec-02-19	Initiated	Goldman	Buy
Oct-30-19	Upgrade	Wells Fargo	Market Perform → Outperform
Jun-11-19	Initiated	Barclays	Overweight
Feb-15-19	Initiated	Wells Fargo	Market Perform
Feb-14-19	Initiated	H.C. Wainwright	Buy
Jan-29-19	Initiated	Stifel	Buy
Nov-16-18	Upgrade	Guggenheim	Neutral → Buy
Sep-17-18	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Apr-20-18	Reiterated	Mizuho	Buy
Mar-27-18	Initiated	Needham	Buy
Mar-05-18	Initiated	Goldman	Buy
Jan-09-18	Downgrade	Guggenheim	Buy → Neutral
Dec-06-17	Initiated	Guggenheim	Buy
Dec-06-17	Reiterated	Mizuho	Buy
Nov-27-17	Initiated	Barclays	Overweight
Nov-17-17	Initiated	Mizuho	Buy
Aug-22-17	Initiated	JMP Securities	Mkt Outperform

View All

Revance Therapeutics Inc Stock (RVNC) Latest News

Feb 11, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesRVNC - PR Newswire

Feb 11, 2025

Deadline Alert: Revance Therapeutics, Inc. (RVNC) Investors - GlobeNewswire

Feb 11, 2025

2025-02-11 | Shareholders that lost money on Revance Therapeutics, Inc. (RVNC) should contact Levi & Korsinsky about pending Class ActionRVNC | Press Release - Stockhouse Publishing

Feb 11, 2025

Feb 10, 2025

2025-02-10 | Shareholders that Lost Money on Revance Therapeutics, Inc. (RVNC) Should Contact Levi & Korsinsky about Pending Class ActionRVNC | Press Release - Stockhouse Publishing

Feb 10, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Feb 10, 2025

2025-02-10 | Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. (RVNC) of a Class Action Lawsuit and an Upcoming Deadline | Press Release - Stockhouse Publishing

Feb 10, 2025

2025-02-10 | RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | Press Release - Stockhouse Publishing

Feb 10, 2025

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc.(RVNC) Shareholders - PR Newswire

Feb 10, 2025

Feb 09, 2025

Class Action Filed Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire

Feb 09, 2025

2025-02-09 | Class Action Filed Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 Deadline to JoinContact Levi & Korsinsky | Press Release - Stockhouse Publishing

Feb 09, 2025

Deltec Asset Management LLC Makes New $304,000 Investment in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat

Feb 09, 2025

Feb 08, 2025

StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - ETF Daily News

Feb 08, 2025

Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by SG Americas Securities LLC - Defense World

Feb 08, 2025

Revance Therapeutics (NASDAQ:RVNC) Completes Merger with Crown Laboratories - Defense World

Feb 08, 2025

Crown Labs completes acquisition of Revance Therapeutics - MSN

Feb 08, 2025

Feb 07, 2025

Crown Laboratories Completes Acquisition of Revance Therapeutics - BioSpace

Feb 07, 2025

Major Aesthetics Industry Shakeup: Crown Labs Takes Over Revance in Strategic Power Move - StockTitan

Feb 07, 2025

Class Action Filed Against Revance Therapeutics, Inc. - GlobeNewswire

Feb 07, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance LawsuitRVNC - The Malaysian Reserve

Feb 07, 2025

StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat

Feb 07, 2025

Crown Labs completes acquisition of Revance Therapeutics By Investing.com - Investing.com Nigeria

Feb 07, 2025

Feb 06, 2025

GLAZER CAPITAL, LLC Acquires Significant Stake in Revance Therap - GuruFocus.com

Feb 06, 2025

RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.

Feb 06, 2025